



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

August 2, 2022

Product Discontinuation Update

Dear Valued Customer,

Pfizer Hospital is committed to providing supply information so that you can plan for patient care. The purpose of this letter is to make you aware of our intent to discontinue the products listed in the table below later this year. The decision to discontinue these products was made only after a thorough assessment by Pfizer Hospital and is based on a variety of business reasons.

While all NDCs listed below, except Adenosine Injection, USP 60 mg/20 mL (3 mg/mL) Single Dose Glass Fliptop Vial, are already listed as discontinued on the U.S. Food and Drug Administration (FDA) [website](#), we still have product releasing into the market through the estimated dates noted in the table below and in our [Availability Report](#). Adenosine Injection, USP 60 mg/20 mL (3 mg/mL) Single Dose Glass Fliptop Vial, NDC 00409-1932-01, is estimated to remain in the market through Q1 2023.

Unit of Sale NDC	Product Description	Unit of Sale Size	Ordering/ Shipping Method	Product Status (as of 8/2/22)	Next and Last Delivery
00409-1932-02	Adenosine Injection, USP 90 mg/30 mL (3 mg/mL) Single Dose Glass Fliptop Vial	1	Wholesalers & Distributors	Limited Supply	No Additional Deliveries
00409-1932-01	Adenosine Injection, USP 60 mg/20 mL (3 mg/mL) Single Dose Glass Fliptop Vial	1	Wholesalers & Distributors	Limited Supply	10/2022
00409-1412-04	Bumetanide Injection, USP 1 mg/4 mL (0.25 mg/mL) Single Dose Glass Fliptop Vial	10	Wholesalers & Distributors	Depleted	8/2022
00409-1412-10	Bumetanide Injection, USP 2.5 mg/10 mL (0.25 mg/mL) Multiple Dose Glass Fliptop Vial	10	Wholesalers & Distributors	Depleted	8/2022

For product availability questions, please reach out to your Pfizer Hospital sales representative or account executive. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 6 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985.

Thank you,

Linna Wilkins
Portfolio Director, Cardiovascular & Steroids
Hospital U.S.

